Back to news

Povofortay® (povorcitinib) Approved in Europe as the First Once-Daily Oral Treatment for Adults with Moderate to Severe Hidradenitis Suppurativa

Business Wire•16/11/2026•16:30 ET
0

Key Highlights

  • ➤European Commission approved Povofortay 45 mg and 75 mg for eligible adults with moderate to severe HS
  • ➤Povofortay became Europe’s first once-daily oral treatment approved for moderate to severe HS
  • ➤STOP-HS trials met Week 12 HiSCR50 endpoints at both studied doses versus placebo
  • ➤Up to 71.4% of patients achieved HiSCR50 through Week 54 across both Phase 3 studies
  • ➤U.S. approval and launch are anticipated in the first quarter of 2027

Expert Statements

Bill Meury, Chief Executive Officer of Incyte

“The European Commission approval of Povofortay marks an important milestone for Incyte, advancing a key growth driver for our business and bringing a new treatment option to people living with HS, a chronic and often debilitating disease”

Bill Meury, Chief Executive Officer of Incyte

“As the first and only once-daily oral treatment approved in the European Union for eligible adults with moderate to severe HS, Povofortay gives physicians an important new option for their patients.”

Professor Dr. Falk Bechara, Ruhr University Bochum, Germany

“HS is a challenging disease to manage, and many patients struggle with the significant burden that affects many aspects of their lives,”

Professor Dr. Falk Bechara, Ruhr University Bochum, Germany

“For clinicians, treatment goals need to go beyond controlling disease activity and also focus on what matters most to patients – genuine improvement in their daily life.”

Professor Dr. Falk Bechara, Ruhr University Bochum, Germany

“This approval gives healthcare professionals and patients an important new option to consider when treating adults with moderate to severe HS, one that could help close the gap that exists in effectively managing this complex disease.”

Povofortay(®) (povorcitinib) Approved in Europe as the First Once-Daily Oral Treatment for Adults with Moderate to Severe Hidradenitis Suppurativa

European Commission approval based on data from Phase 3 STOP-HS1 and STOP-HS2, which showed that Povofortay(®) (povorcitinib) met the primary endpoint at Week 12 and delivered clinically meaningful, durable responses through Week 54 and was well tolerated (1)(,2)

Get started

Create a free account to read the full story.

Sign Up

Already have an account? Log in